GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
GSK's mRNA flu vaccine is advancing to Phase 3 trials after outperforming standard shots in Phase 2.
5 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 5 separate news trends connected to Vaccine Development, spanning June 19, 2026 through September 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 51 article observations and 49 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
GSK's mRNA flu vaccine is advancing to Phase 3 trials after outperforming standard shots in Phase 2.
The Ebola outbreak in the Democratic Republic of Congo is now the deadliest in the country’s history
Scientists are testing vaccines to intercept colon and pancreatic cancer before it starts
Recent breakthroughs in mRNA technology have brought an HIV vaccine closer to reality.
A race to develop vaccines for the Bundibugyo strain of Ebola is underway, including a candidate that has existed for 15 years.